London – A consortium led by British gene medicince company Ark Therapeutics Group plc has received a EUR5.3m grant from the European Commission’s 7th Framework Programme to fund research to combine Ark’s technology covering adenoviral-delivered gene therapeutics with a “pro-healing or regenerative” coronary stent. The combination of biotechnology and stent technology is meant to allow a predictable degradation to deliver the therapeutics to the coronary artery after a heart attack.The project also aims to investigate healing an artery through the regeneration of native tissue. The consortium includes VC firm Magnus Invention Management Ltd. and QualiMed Innovative Medizinprodukte GmbH (Winsen, Germany), – which will manufacture the stent – as well as participation from researchers at University College London Division of Medicine, Yale University and the University of Eastern Finland. The four-year project is slated to start in November. Ark will receive a1.1m for its contribution. “We hope that this research will offer new hope to sufferers of heart disease,” said Ark CSO John Martin. The project was succesfully chosen from more than 40 applications across Europe.